Cardiff Oncology (CRDF) Common Equity (2011 - 2026)

Cardiff Oncology has reported Common Equity for 15 years, with the latest figure at $45.4 million in Q4 2025.

• Quarterly Common Equity fell 45.28% year-over-year to $45.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $45.4 million (down 45.28% YoY) and the FY2025 annual result came in at $45.4 million, down 45.28% from the prior year.
• Common Equity declined to $45.4 million in Q4 2025 per CRDF's latest filing, from $48.8 million in the prior quarter.
• Over five years, Common Equity peaked at $140.4 million in Q4 2021 and troughed at $45.4 million in Q4 2025.
• A 5-year average of $90.4 million and a median of $84.8 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2021 and 2025: Common Equity surged 1932.52% in 2021, then tumbled 45.28% in 2025.
• Over 5 years, Common Equity stood at $140.4 million in 2021, then decreased by 24.27% to $106.3 million in 2022, then sank by 34.42% to $69.7 million in 2023, then grew by 18.94% to $82.9 million in 2024, then sank by 45.28% to $45.4 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $45.4 million, $48.8 million, and $58.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.